SPRY · ARS Pharmaceuticals, Inc.
$4.03
-6.71% last session
End-of-day data · close of 2026-10-23
Market cap
<$1M
Enterprise value
<$1M
Trailing P/E
—
Forward P/E
-4.5
Dividend yield
0.0%
Beta
1.08
Avg volume
2M
Employees
0K
Daily Change %
-6.71%
5 Days Change
-4.73%
10 Days Change
2.54%
30 Days Change
-2.89%
60 Days Change
-29.55%
Month to Day Change
-2.18%
Year to Day Change
-65.41%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — SPRY
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-08-13
Latest call per bank · past 12 months
Recent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-13 | Leerink Partners | Maintains | Outperform | $24.00 → $18.00 |
| 2026-06-25 | Leerink Partners | Maintains | Outperform | $25.00 → $24.00 |
| 2026-05-28 | Cantor Fitzgerald | Maintains | Overweight | $12.00 → $30.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-10-23
- neutral: RSI (14): RSI is 41 — neutral momentum, neither overbought nor oversold.
- bearish: Price vs 50-day MA: Trading 16.2% below the 50-day MA ($4.81).
- bearish: Price vs 200-day MA: Trading 46.9% below the 200-day MA ($7.59).
- bearish: MA cross: The 50-day MA sits below the 200-day MA (death-cross regime) — the longer-term trend points down.
- bullish: MACD (12,26,9): MACD histogram is positive (+0.05) — short-term momentum is improving.
- bearish: 52-week range: Price is within 10% of the 52-week low ($3.93).
SPRY Price Chart
Loading chart for SPRY…
Fundamentals
About ARS Pharmaceuticals, Inc.
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$133B 18.1% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$83B 6.5% YTD
MRNA
Moderna, Inc.
$80B 587.1% YTD
ARGX
argenx SE
$55B 4.1% YTD
ONC
BeOne Medicines Ltd.
$43B 25.8% YTD
RVMD
Revolution Medicines, Inc.
$40B 135.6% YTD
RPRX
Royalty Pharma plc
$37B 67.3% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$30B -42.8% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.